SEC Form 4
Aldeyra Therapeutics, Inc. (ALDX) insider trading
In the 12 months to Nov 15, 2026, 3 ALDX insiders reported open-market purchases of $659.0K across 5 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $659.0K
- 5 filings
Who traded ALDX, and when
- Purchase
ALDX daily close from Nov 17, 2025 to Nov 13, 2026, between $0.56 and $5.62, last $0.64. 0 sale and 5 purchase filings by 3 insiders, marked at their filing dates. Todd C. Brady, President and CEO: bought $418.5K across 1 filing, first filed Jun 5, 2026, last Jun 5, 2026. Richard Douglas, Director: bought $226.9K across 2 filings, first filed Mar 20, 2026, last Nov 13, 2026. Michael Alfieri, Principal Financial Officer: bought $13.6K across 2 filings, first filed Mar 19, 2026, last Nov 13, 2026.
Largest mark · tap a row for others
Todd C. Brady · President and CEO
Purchase $418,450
250,000 shares at $1.67 avg
Filed Jun 5, 2026 · traded Jun 3
Close on filing date $1.63
Todd C. Brady · President and CEO
President and CEO
$418.5K boughtRichard Douglas · Director
Director
$226.9K boughtMichael Alfieri · Principal Financial Officer
Principal Financial Officer
$13.6K boughtOpen-market trades
5 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Todd C. Brady | President and CEO | — | $418.5K | 1 | — | |
| Richard Douglas | Director | — | $226.9K | 2 | — | |
| Michael Alfieri | Principal Financial Officer | — | $13.6K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Richard Douglas Director | Purchase | 200,000 | $0.64 | $128.9K | 395,000 | |
traded | Michael Alfieri Principal Financial Officer | Purchase | 10,000 | $0.65 | $6.5K | 17,500 | |
traded | Todd C. Brady President and CEO | Purchase | 250,000 | $1.67 | $418.5K | 1,721,298 | |
traded | Richard Douglas Director | Purchase | 70,000 | $1.40 | $98.0K | 195,000 | |
traded | Michael Alfieri Principal Financial Officer | Purchase | 5,000 | $1.42 | $7.1K | 7,500 |
GET /stocks/filings/vX/form-4?tickers=ALDX&filing_date.gte=2025-11-15&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ALDX"
],
"issuer_cik": "0001341235",
"owner_cik": "0001021015",
"accession_number": "0001193125-26-460743",
"form_type": "4",
"filing_date": "2026-11-13",
"period_of_report": "2026-11-11",
"issuer_name": "Aldeyra Therapeutics, Inc.",
"issuer_trading_symbol": "ALDX",
"owner_name": "DOUGLAS RICHARD",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-11",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 200000,
"transaction_price_per_share": 0.6445,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 395000,
"transaction_value": 128899.99999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.6362 to $0.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"ALDX"
],
"issuer_cik": "0001341235",
"owner_cik": "0001744687",
"accession_number": "0001193125-26-460801",
"form_type": "4",
"filing_date": "2026-11-13",
"period_of_report": "2026-11-11",
"issuer_name": "Aldeyra Therapeutics, Inc.",
"issuer_trading_symbol": "ALDX",
"owner_name": "Alfieri Michael",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Principal Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-11",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 10000,
"transaction_price_per_share": 0.65,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 17500,
"transaction_value": 6500,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Aldeyra Therapeutics, Inc.'s CEO sold stock?
No. Todd C. Brady (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is ALDX’s insider data?
These are ALDX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ALDX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ALDX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.